A new antibiotic, rosamicin, classified as a macrolide, has been isolated from the fermentation broth of a new species of Micromonospora, M. rosaria.
The first macrolide antibiotic to be isolated from a species of Micromonospora was megalomicin, produced by M. megalomicea.1} A new macrolide antibiotic unrelated to megalomicin and named rosamicin has now been isolated from the fermentation broth of another new species of the genus Micromonospora. This paper presents initial data on the taxonomyof this neworganism, and primary data concerning the chemical and biological properties of rosamicin.
Materials and Methods
The organism which produces rosamicin is a newspecies of Micromonospora, named M. rosaria and assigned NRRLNo. 3718. This culture was isolated from a. soil sample:
obtained from Little Thicket, San Jacinto County, Texas.
The colonial morphology of a 14-day old culture was determined after incubation at 24~26°C on an agar medium consisting of N-Z amine type A, 3%, dextrose, 1%; and agar, 1.5 %. Macroscopically, no aerial mycelia are evident; colonies are slightly raised, granular to weakly folded.
Growth is fair, glistening, and no diffusible pigment is. produced. On an agar medium composed of yeast extract, 1% and glucose 1%, a rosecolored diffusible pigment is produced.
The mycelia are regularly branched averaging 10~20 ju in length and 0.6 jjl in diameterNumerous chlamydospores are produced, up to 2ju in diameter. Conidia are not observed on the N-Z amine medium. The laboratory fermentation of M. rosaria is carried out in two stages, as follows: a) Germination stage: A loopful of M. rosariaculture from an agar slant is used to inoculate a 300-ml flask containing 100 ml of the following sterile medium: beef extract, 3 g; tryptose, 5g; yeast extract, 5g; dextrose, 1g; potato starch, 24g, calcium carbonate, 2g; tap water, 1,000ml. The flask and its contents are incubated for 72 hours at 35°C on a rotary shaker with 2-inch (5.1 cm) stroke at 280rpm. The microbiological assay of rosamicin is a cylinder cup assay using Bacillus subtilis ATCC6633 as the test organism.
The physical conditions of the assay consist of a base layer of 21 ml and a seed layer of 4 ml of Antibiotic Medium (Difco) No. 5. A commercial source of B. subtilis spores is used as the inoculum.
The standard curve used in the assay has the following antibiotic concentrations: 0.64, 0.8, 1.0 (reference point), 1.25 and 1.56meg per ml. The diluent used in the preparation of all dilutions is 0.1 M phosphate buffer (pH 8.0).
The reference standard prepared as described has an assigned potency of 1,000 meg/mg. One meg of this preparation in 1 ml of 0.1 Mphosphate buffer analyzed under the conditions of this assay will elicit a zonal response of 17.8±1.0mm.The working standard is a preparation having a potency of 775 meg/mgassayed against the reference standard.
The in vitro activity of rosamicin was studied by conventional tube dilution procedures using yeast beef broth at pH 7.4.
The protective activity of rosamicin was tested in male CF-1 mice weighing approximately 20g each. The antibiotic was given as a suspension or solution in an aqueous vehicle containing 0.5 % carboxy methyl cellulose in two doses ; shortly before, and 4 hours after intraperitoneal infection with bacteria. Infected, non-treated mice generally died 18
hours after infection while survivors in treated groups were determined 48 hours after infection.
Results and Discussion
Isolation and Characterization Rosamicin is isolated from the fermented broth by a solvent extraction procedure. A 60-liter fermentation is adjusted to a pH of 9.5 with sodium hydroxide and is extracted two times using 2 volumes of ethyl acetate, each time, for each volume of whole broth.
After separation, the solvent phase is concentrated to a volume of precipitate. The weight of the combined precipitate is about 1.5 g. Material produced in this way has been assigned a working potency of about 700 mcg/mgof rosamicin complex according to the bioassay procedure previously -described.
Characterization and Properties of the Antibiotic Ghromatography in a variety of systems differentiated rosamicin from all other groups of compoundsexcept the macrolide group of antibiotics. Ghromatographyon thin-layer plates using a solvent mixture consisting of chloroform-methanol-17 % ammonia, 2 : 1 : 1 (lower phase), shows the similarity of rosamicin with other macrolide Table 2 .
Bioautography following chromatography on thin-layer silica gel plates using a By this method, rosamicin was separated and isolated after pooling similar active fractions, drying, dissolving in acetone and precipitating with ethyl ether. The mother liquor is nowevaporated to dryness yielding the antibiotic as a white powder. Rosamicin at this stage exhibits a denned potency of 1,000 mcg/mg. The chemical and physical properties of rosamicin are summarized in Table 3 and solubility characteristics are shown in Table 4 . Desosamine was found to be present (procedure of Flynn et al2)) and identical to an authentic sample by paper chromatographic comparison using a solvent mixture of butanol-pyridine-acetic acid-water (6:4: 1 :3). Additional chemical studies and elucidation of the structure of rosamicin are given in Reimannet al.z) A stability study comparing rosamicin base with erythromycin base is shown in Table 5 . Buffered solutions containing approximately 250 mcg/ml of each antibiotic were made up in a range of pH 2.2-10. Samples were taken at 0 and 30 minutes 
In Vitro Antimicrobial Activity of Rosamicin
The results of in vitro tests in which rosamicin was compared with erythromycin and megalomicin A are shown in Table 6 and demonstrate The effect of pH on the in vitro activity of rosamicin was tested against a select group of organisms (Table 7) . As with other macrolides, rosamicin has greater activity at higher pH levels. Of interest is the fact that the greatest shift in activity for the antibiotic occurs around pH7.5, while the shift for erythromycin occurs at pH 7.7 and for megalomicin A it occurs at pH 7.8~8.0. Rosamicin thus has less diminution of activity in the physiological pH range.
The antibiotic was studied in vitro against a limited number of erythromycin-' resistant S. aureus and S. pyogenes strains ( (Table  5) , 625 mg/kg when given subcutaneously, and 155 mg/kg intravenously.
The intraperitoneal LD50 for rosamicin is similar to erythromycin and megalomicin A, but it is more toxic than these two antibiotics when given subcutaneously. This may be due to the aqueous solubility and improved absorption of rosamicin compared to the low solubility of the base forms of megalomicin A and erythromycin.
Based on the biological data available, rosamicin appears to have in vitro and in vivo properties typical of other macrolides with better gram-negative activity and activity against some erythromycin-resistant strains. These data, along with its apparent stability, suggest that further investigation of rosamicin is warranted.
